Loading…
← CockpitCompetitor Analysis › 002007.SZ Hualan Biological Engineering Inc. Class AOpen in the cockpit ↗

Hualan Biological Engineering Inc. Class A002007.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.

≈ A Chinese CSL/Grifols plus a vaccine businessMomentum strong 65
Mkt cap
$3.20B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$20.3M
20-day average traded
Fwd P/E
26.7×
forward earnings
ROIC−WACC
-2.9 pp
WACC 8.6%
Hurdle
+18 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥11.80
1D+0.6%
1W-2.2%
1M-9.2%
3M-12.0%
6M-16.8%
YTD-22.0%
1Y-28.0%
ATR %2.2%
52w lowhigh30.6% off high

What Hualan Biological Engineering does

Major Chinese plasma-products and vaccine maker, producing albumin, immunoglobulin and influenza and other vaccines.

Sells albumin and immunoglobulin made from collected plasma, so output depends on how much its state-licensed collection stations can gather, and regulators cap new station licences. Vaccines, led by flu shots, are a second income line with seasonal demand through disease-control centres and hospitals.

In one line: A Chinese CSL/Grifols plus a vaccine business.

Products and services

  • Human albumin
  • Immunoglobulin
  • Influenza & other vaccines (Hualan Vaccine)
  • Coagulation factors

Customers

  • Hospitals
  • CDC/vaccination programs
  • Distributors

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Plasma products & vaccines

What could go right

  • Plasma collection volume growth
  • Vaccine demand

What could go wrong

  • Plasma license/collection-volume caps
  • Vaccine procurement price pressure

Moat: narrow (regulatory licence, scale). One of China's largest plasma-collection networks, capacity that is capped and licensed by the state.

Headquarters: Xinxiang, China · Employees: 4,117

Named competitors

Hualan Biological Engineering at a glance

Size Hualan Biological Engineering (002007.SZ) is a China Health Care company (Biotechnology) with a market value of $3.20B, the 753rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.80 on 18 Nov 2026.

Performance Over six months the shares fell 16.8%, against +5.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 10.8% over the last twelve months (peer median +8.9%); the operating margin is 16.9% (peer median -3.2%).

Valuation It trades at 26.7× forward earnings against a peer median of 31.3× (4th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.9 points below its cost of capital (8.6% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 104002007.SZ 84
Six months, rebased to 100: Hualan Biological Engineering against the median of its 20 peers (local-currency closes).

Hualan Biological Engineering financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.80BCN¥4.58BCN¥4.36BCN¥5.32BCN¥4.50B
Revenue growth—+5%-18%+18%—
Gross profitCN¥1.98BCN¥2.51BCN¥2.56BCN¥3.59BCN¥2.84B
EBITDAn/aCN¥1.41BCN¥1.45BCN¥2.08BCN¥1.51B
Net incomeCN¥587MCN¥940MCN¥1.09BCN¥1.48BCN¥1.08B
Free cash flowCN¥804MCN¥945MCN¥939MCN¥680MCN¥632M
Capital expenditureCN¥181MCN¥197MCN¥256MCN¥753MCN¥394M
Total debtCN¥628MCN¥547MCN¥1.01BCN¥1.01BCN¥1.13B

Quarterly statements and history in the cockpit →

Hualan Biological Engineering competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%VIRPXERSELVN6919ADMATLXDYNIOVADNLIRUBICONIRON2228ABCLBAVARLAY6031279688TNGX002007.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Hualan Biological Engineering is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×VIRPXERSADMATLX600161RUBICONBAVA603127002007.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hualan Biological Engineering is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%VIRPXERSADMA600161BAVA002007.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hualan Biological Engineering is the large dot.

Hualan Biological Engineering competitors and peer comparison

Head to head with its named competitors (002007.SZ vs 002252.SZ vs 600161.SS vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%26.7×15.8%
Shanghai RAAS Blood Products 002252.SZ$4.57B-15%-22%17%12.8×n/a
Beijing Tiantan Biological Products 600161.SS$3.47B-13%-13%21%33.1×2.2%
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%

How Hualan Biological Engineering compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hualan Biological Engineering against its 20 peers (data as of 18 Nov 2026)
Measure002007.SZPeer medianRank in peer set
1-month return-9.2%-4.6%7th lowest of 21
6-month return-16.8%+5.5%3rd lowest of 21
Distance from 52-week high-30.6%-27.8%10th lowest of 21
Revenue growth (TTM)-10.8%+8.9%4th lowest of 17
Operating margin16.9%-3.2%5th highest of 17
Forward P/E26.7×31.3×4th cheapest of 9
Growth the price implies (Req g, 7 yrs)15.8%2.2%2nd most demanding of 6
Growth delivered (Del g)-1.8%+27.4%lowest of 6
Hurdle (Req g minus delivered)+17.6 pp-31.7 ppmost demanding of 6
ROIC minus cost of capital-2.9 pp-9.4 pp7th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%29.4×n/an/a
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a

Questions

Who are Hualan Biological Engineering's main competitors?
Named competitors: Shanghai RAAS Blood Products (002252.SZ), Beijing Tiantan Biological Products (600161.SS), CSL Behring (CSL.AX), Grifols (GRF.MC). The cockpit's measured peer set (industry) also includes Virbac (VIRP.PA), Xeris Biopharma (XERS), Enliven Therapeutics (ELVN), Caliway Biopharmaceuticals (6919.TW), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX.AX).
Is Hualan Biological Engineering expensive compared with its peers?
On forward p/e it trades at 26.7× against a peer median of 31.3×, 4th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Hualan Biological Engineering stock performed?
Over six months to 18 Nov 2026 the shares returned -16.8% against +5.5% for the median peer; over one year -28.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.